Study Objectives: A reduction in core temperature and an increase in the distal-proximal skin
gradient (DPG) are reported to be associated with shorter sleep onset latencies (SOL) and …

Melatonin, a chronobiotic that participates in the control of the circadian system, is known for
its sleep-promoting effects, which include shortening of sleep latency and lengthening of …

Objective To investigate the effect of ramelteon on sleep and daytime functioning among
individuals with traumatic brain injury (TBI). Design A double-blind, placebo-controlled study …

Objectives Residual next-day effects of sleep-promoting drugs are common and an
important safety issue. Lemborexant is a dual orexin receptor antagonist approved in the …

In this case series of 5 alcohol-dependent patients with insomnia who had initiated
abstinence, a 4-week course of ramelteon 8 mg nightly was associated with markedly …

Rationale: Primary treatment of obstructive sleep apnea can be accompanied by a
persistence of excessive sleepiness despite adherence. Furthermore, effectiveness of sleep …

Objective To evaluate the effects of ramelteon, an MT1/MT2 melatonin receptor agonist used
to treat insomnia, on endocrine function in adults with chronic insomnia. Methods This was a …

Abstract Ramelteon (Rozerem; Takeda), a melatonin receptor agonist, was approved by the
US FDA for the treatment of insomnia in July 2005. In contrast to other widely used drugs for …

Study Objectives: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved
in the United States and European Union to treat excessive daytime sleepiness in patients …

Background: Seltorexant is a potent and selective antagonist of the orexin-2 receptor that is
being developed for the treatment of insomnia and major depressive disorder. Aims: The …